(688085)"Shanghai Sanyou Medical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 688085 · · 19 pages · Chinese
Summary by 6ix AI
The report indicates a decline in net profit compared to the same period last year, attributed to various costs including share-based payments and asset impairments. The company achieved significant revenue growth in its domestic and international operations despite the overall profit decrease.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shanghai Sanyou Medical Co. Ltd. on 6ix
Earlier from Shanghai Sanyou Medical
- (688085)"Shanghai Sanyou Medical Co., Ltd."Announcement on Progress in Repurchasing Shares through Call Auction
- (688085)"Shanghai Sanyou Medical Co., Ltd."Announcement on the Satisfaction of Vesting Conditions for the First Vesting Period under the 2025 Restricted Share Incentive Plan
- (688085)"Shanghai Sanyou Medical Co., Ltd."Announcement on Resolutions of the 14th Meeting of the 4th Board of Directors
- (688085)"Shanghai Sanyou Medical Co., Ltd."Announcement on Cancellation of Certain Restricted Shares under 2025 Restricted Share Incentive Plan
- (688085)"Shanghai Sanyou Medical Co., Ltd."Announcement on Adjustment of the Grant Price and Grant Quantity under the 2025 Restricted Share Incentive Plan
Later from Shanghai Sanyou Medical
- (688085)"Shanghai Sanyou Medical Co., Ltd."Announcement on Vesting Results for the First Vesting Period under the 2025 Restricted Share Incentive Plan and Listing of Shares
- (688085)"Shanghai Sanyou Medical Co., Ltd."Announcement on Attending the Q3 2026 Collective Performance Briefing of Listed Companies in Shanghai Jurisdiction
Follow Shanghai Sanyou Medical into a list and get an email when it puts out news.
Follow Shanghai Sanyou Medical